$5.75 Billion is the total value of Avoro Capital Advisors LLC's 46 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Buy | MIRATI THERAPEUTICS INC | $807,650,000 | +0.9% | 5,000,000 | +7.0% | 14.05% | +1.6% |
| ARGX | Buy | ARGENX SEsponsored adr | $284,963,000 | +11.8% | 946,500 | +2.3% | 4.96% | +12.6% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $277,915,000 | -1.1% | 4,075,000 | +0.6% | 4.84% | -0.4% |
| ASND | New | ASCENDIS PHARMAsponsored adr | $249,945,000 | – | 1,900,000 | +100.0% | 4.35% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $236,782,000 | -6.5% | 9,100,000 | +13.8% | 4.12% | -5.8% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $186,576,000 | +16.4% | 2,400,000 | +11.6% | 3.25% | +17.3% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $169,520,000 | – | 1,000,000 | +100.0% | 2.95% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $120,018,000 | -0.8% | 12,450,000 | +1.6% | 2.09% | -0.1% |
| CNST | Buy | CONSTELLATION PHARMACEUTICALS INC | $108,498,000 | +57.2% | 3,210,000 | +8.8% | 1.89% | +58.3% |
| KURA | Buy | KURA ONCOLOGY INC | $86,319,000 | -23.7% | 4,140,000 | +3.5% | 1.50% | -23.1% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $63,531,000 | +48.1% | 1,005,230 | +0.5% | 1.10% | +49.1% |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $62,153,000 | – | 3,311,434 | +100.0% | 1.08% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $51,510,000 | -7.9% | 3,000,000 | +20.0% | 0.90% | -7.2% |
| MNKD | Buy | MANNKIND CORP | $47,034,000 | +60.0% | 8,630,000 | +15.1% | 0.82% | +61.0% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS INC | $39,099,000 | -2.4% | 1,068,000 | +19.6% | 0.68% | -1.7% |
| PRAX | Buy | PRAXIS PRECISION MEDICINES INC | $29,248,000 | -38.3% | 1,600,000 | +0.2% | 0.51% | -37.9% |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $11,105,000 | – | 500,000 | +100.0% | 0.19% | – |
| ARPO | New | AERPIO PHARMACEUTICALS INC | $7,605,000 | – | 4,500,000 | +100.0% | 0.13% | – |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $3,360,000 | – | 240,000 | +100.0% | 0.06% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCcall | $1,425,000 | – | 150,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.